Edward E Walsh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6603199/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine, 2020, 383, 2439-2450.	27.0	2,107
2	Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults. New England Journal of Medicine, 2005, 352, 1749-1759.	27.0	1,668
3	Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nature Immunology, 2000, 1, 398-401.	14.5	1,482
4	The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infectious Diseases, The, 2018, 18, e295-e311.	9.1	355
5	Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. PLoS Pathogens, 2015, 11, e1005318.	4.7	215
6	Risk Factors for Severe Respiratory Syncytial Virus Infection in Elderly Persons. Journal of Infectious Diseases, 2004, 189, 233-238.	4.0	183
7	Humoral and Mucosal Immunity in Protection from Natural Respiratory Syncytial Virus Infection in Adults. Journal of Infectious Diseases, 2004, 190, 373-378.	4.0	163
8	Human Metapneumovirus Infections in Adults. Archives of Internal Medicine, 2008, 168, 2489.	3.8	158
9	Superiority of Transcriptional Profiling Over Procalcitonin for Distinguishing Bacterial From Viral Lower Respiratory Tract Infections in Hospitalized Adults. Journal of Infectious Diseases, 2015, 212, 213-222.	4.0	146
10	Clinical Impact of Human Coronaviruses 229E and OC43 Infection in Diverse Adult Populations. Journal of Infectious Diseases, 2013, 208, 1634-1642.	4.0	145
11	Respiratory Syncytial Virus Transplacental Antibody Transfer and Kinetics in Mother-Infant Pairs in Bangladesh. Journal of Infectious Diseases, 2014, 210, 1582-1589.	4.0	134
12	Clinical Features of Influenza A Virus Infection in Older Hospitalized Persons. Journal of the American Geriatrics Society, 2002, 50, 1498-1503.	2.6	121
13	Viral Shedding and Immune Responses to Respiratory Syncytial Virus Infection in Older Adults. Journal of Infectious Diseases, 2013, 207, 1424-1432.	4.0	110
14	Serum Procalcitonin Measurement and Viral Testing to Guide Antibiotic Use for Respiratory Infections in Hospitalized Adults: A Randomized Controlled Trial. Journal of Infectious Diseases, 2015, 212, 1692-1700.	4.0	103
15	Respiratory Syncytial Virus Infection in Adult Populations. Infectious Disorders - Drug Targets, 2012, 12, 98-102.	0.8	101
16	Is Clinical Recognition of Respiratory Syncytial Virus Infection in Hospitalized Elderly and Highâ€Risk Adults Possible?. Journal of Infectious Diseases, 2007, 195, 1046-1051.	4.0	96
17	Experimental infection of humans with A2 respiratory syncytial virus1. Antiviral Research, 2004, 63, 191-196.	4.1	86
18	Respiratory Syncytial Virus Infection. Clinics in Chest Medicine, 2017, 38, 29-36.	2.1	72

EDWARD E WALSH

#	Article	IF	CITATIONS
19	Detection of Respiratory Viruses in Sputum from Adults by Use of Automated Multiplex PCR. Journal of Clinical Microbiology, 2014, 52, 3590-3596.	3.9	64
20	Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017–2020. Clinical Infectious Diseases, 2022, 74, 1004-1011.	5.8	61
21	Age related differences in humoral immune response to respiratory syncytial virus infection in adults. Journal of Medical Virology, 2004, 73, 295-299.	5.0	58
22	Transcriptomic Biomarkers to Discriminate Bacterial from Nonbacterial Infection in Adults Hospitalized with Respiratory Illness. Scientific Reports, 2017, 7, 6548.	3.3	54
23	Should clinical case definitions of influenza in hospitalized older adults include fever?. Influenza and Other Respiratory Viruses, 2015, 9, 23-29.	3.4	53
24	Reverse transcription polymerase chain reaction (RT-PCR) for diagnosis of respiratory syncytial virus infection in adults: Use of a single-tube ?hanging droplet? nested PCR. Journal of Medical Virology, 2001, 63, 259-263.	5.0	50
25	Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults. , 1999, 59, 221-226.		45
26	The Effect of Steroid Use in Hospitalized Adults With Respiratory Syncytial Virus-Related Illness. Chest, 2011, 140, 1155-1161.	0.8	45
27	Vaccination programs for older adults in an era of demographic change. European Geriatric Medicine, 2018, 9, 289-300.	2.8	43
28	Respiratory syncytial virus–associated illness in adults with advanced chronic obstructive pulmonary disease and/or congestive heart failure. Journal of Medical Virology, 2019, 91, 65-71.	5.0	43
29	A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine. Journal of Infectious Diseases, 2022, 225, 1357-1366.	4.0	38
30	Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection. Journal of Infectious Diseases, 2018, 218, 208-217.	4.0	34
31	Development of a Global Respiratory Severity Score (GRSS) for Respiratory Syncytial Virus Infection in Infants. Journal of Infectious Diseases, 2017, 215, jiw624.	4.0	32
32	CX3CR1 as a respiratory syncytial virus receptor in pediatric human lung. Pediatric Research, 2020, 87, 862-867.	2.3	32
33	Microbiome-Transcriptome Interactions Related to Severity of Respiratory Syncytial Virus Infection. Scientific Reports, 2019, 9, 13824.	3.3	30
34	The Healthy Infant Nasal Transcriptome: A Benchmark Study. Scientific Reports, 2016, 6, 33994.	3.3	25
35	Delayed Diagnosis of Respiratory Syncytial Virus Infections in Hospitalized Adults: Individual Patient Data, Record Review Analysis and Physician Survey in the United States. Journal of Infectious Diseases, 2019, 220, 969-979.	4.0	24
36	Syncope, Near Syncope, or Nonmechanical Falls as a Presenting Feature of COVID-19. Annals of Emergency Medicine, 2020, 76, 115-117.	0.6	22

EDWARD E WALSH

#	Article	IF	CITATIONS
37	Cost determinants among adults hospitalized with respiratory syncytial virus in the United States, 2017–2019. Influenza and Other Respiratory Viruses, 2022, 16, 151-158.	3.4	22
38	Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccine in Patients with Hypersensitivity to First Dose. Open Forum Infectious Diseases, 2021, 8, ofab507.	0.9	20
39	Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial. PLoS ONE, 2016, 11, e0152986.	2.5	19
40	Can Analysis of Routine Viral Testing Provide Accurate Estimates of Respiratory Syncytial Virus Disease Burden in Adults?. Journal of Infectious Diseases, 2017, 215, 1706-1710.	4.0	19
41	Association of Dynamic Changes in the CD4 T-Cell Transcriptome With Disease Severity During Primary Respiratory Syncytial Virus Infection in Young Infants. Journal of Infectious Diseases, 2017, 216, 1027-1037.	4.0	17
42	Airway Gene Expression Correlates of Respiratory Syncytial Virus Disease Severity and Microbiome Composition in Infants. Journal of Infectious Diseases, 2021, 223, 1639-1649.	4.0	17
43	Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and postâ€discharge assessed by Respiratory Intensity and Impact Questionnaire. Influenza and Other Respiratory Viruses, 2022, 16, 79-89.	3.4	16
44	Mutation of Respiratory Syncytial Virus G Protein's CX3C Motif Attenuates Infection in Cotton Rats and Primary Human Airway Epithelial Cells. Vaccines, 2019, 7, 69.	4.4	15
45	CX3CR1 Engagement by Respiratory Syncytial Virus Leads to Induction of Nucleolin and Dysregulation of Cilium-Related Genes. Journal of Virology, 2021, 95, .	3.4	14
46	Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial Virus. PLoS ONE, 2016, 11, e0153019.	2.5	14
47	Can serum procalcitonin levels help interpret indeterminate chest radiographs in patients hospitalized with acute respiratory illness?. Journal of Hospital Medicine, 2013, 8, 61-67.	1.4	9
48	Clinical and Genomic Features of the First Cases of Elizabethkingia anophelis Infection in New York, Including the First Case in a Healthy Infant Without Previous Nosocomial Exposure. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 269-271.	1.3	9
49	Temporal, Spatial, and Epidemiologic Relationships of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Gene Cycle Thresholds: A Pragmatic Ambi-directional Observation. Clinical Infectious Diseases, 2021, 73, e3133-e3135.	5.8	9
50	Temporal Dysbiosis of Infant Nasal Microbiota Relative to Respiratory Syncytial Virus Infection. Journal of Infectious Diseases, 2021, 223, 1650-1658.	4.0	9
51	A cluster-control approach to a coronavirus disease 2019 (COVID-19) outbreak on a stroke ward with infection control considerations for dementia and vascular units. Infection Control and Hospital Epidemiology, 2021, 42, 1-7.	1.8	9
52	Aims, Study Design, and Enrollment Results From the Assessing Predictors of Infant Respiratory Syncytial Virus Effects and Severity Study. JMIR Research Protocols, 2019, 8, e12907.	1.0	9
53	Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein. Human Vaccines and Immunotherapeutics, 2020, 16, 2007-2017.	3.3	7
54	Effectiveness of various cleaning strategies in acute and long-term care facilities during novel corona virus 2019 disease pandemic-related staff shortages. PLoS ONE, 2022, 17, e0261365.	2.5	7

EDWARD E WALSH

#	Article	IF	CITATIONS
55	Hypergammaglobulinemia and Impaired Transplacental Transfer of Respiratory Syncytial Virus Antibody in Papua New Guinea. Pediatric Infectious Disease Journal, 2019, 38, e199-e202.	2.0	6
56	Airway gene-expression classifiers for respiratory syncytial virus (RSV) disease severity in infants. BMC Medical Genomics, 2021, 14, 57.	1.5	5
57	Emergence of the E484K Mutation in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lineage B.1.1.345 in Upstate New York. Clinical Infectious Diseases, 2022, 74, 909-912.	5.8	5
58	733. Incidence and Evaluation of the Change in Functional Status Associated with Respiratory Syncytial Virus Infection in Hospitalized Older Adults. Open Forum Infectious Diseases, 2018, 5, S263-S263.	0.9	3
59	Respiratory Syncytial Virus: An Old Foe in a New Era. Journal of Infectious Diseases, 2020, 222, 1245-1246.	4.0	3
60	Diagnosis of Streptococcus pneumoniae infection using circulating antibody secreting cells. PLoS ONE, 2021, 16, e0259644.	2.5	3
61	The Challenge of Respiratory Syncytial Virus Human Challenge Studies. New England Journal of Medicine, 2022, 386, 696-697.	27.0	3
62	A systems genomics approach uncovers molecular associates of RSV severity. PLoS Computational Biology, 2021, 17, e1009617.	3.2	3
63	Evaluation of Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunizations in Patients with B-Cell Malignancies. Blood, 2021, 138, 4681-4681.	1.4	1
64	Compassionate Use Experience with High Titer RSV Immunoglobulin (RSV-IVIG) in RSV Infected Immunocompromised Persons. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
65	LytA-Positive Streptococcus mitis/oralis Confound Interpretation of Pneumococcal Colonization Studies. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
66	Can Analysis of Routine Viral Testing Provide Accurate Estimates of Respiratory Syncytial Virus (RSV) Disease Burden in Adults?. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
67	Mitigating Candida auris at a Busy Community Hospital: AÂQuasi-Experimental Near Real-Time Approach. Open Forum Infectious Diseases, 2017, 4, S72-S72.	0.9	0
68	Unbiased analysis of peripheral blood mononuclear cells reveals CD4 T cell response to RSV matrix protein. Vaccine: X, 2020, 5, 100065.	2.1	0
69	Early Life RSV: Can Vaccines Help Fix Societal Ills?. Pediatrics, 2021, 147, e2020038356.	2.1	Ο